Suppr超能文献

入组国家收入水平与患者资料、方案完成情况及试验终点之间的关系。

Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points.

作者信息

Greene Stephen J, Hernandez Adrian F, Sun Jie-Lena, Butler Javed, Armstrong Paul W, Ezekowitz Justin A, Zannad Faiez, Ferreira João Pedro, Coles Adrian, Metra Marco, Voors Adriaan A, Califf Robert M, O'Connor Christopher M, Mentz Robert J

机构信息

Duke Clinical Research Institute, Durham, NC (S.J.G., A.F.H., J.-L.S., A.C., R.M.C., C.M.O., R.J.M.).

Division of Cardiology, Duke University School of Medicine, Durham, NC (S.J.G., A.F.H., R.M.C., R.J.M.).

出版信息

Circ Cardiovasc Qual Outcomes. 2018 Oct;11(10):e004783. doi: 10.1161/CIRCOUTCOMES.118.004783.

Abstract

BACKGROUND

Globalization of clinical trials fosters inclusion of higher and lower income countries, but the influence of enrolling country income level on heart failure trial performance is unclear. This study sought to evaluate associations between enrolling country income level, acute heart failure patient profile, protocol completion, and trial end points.

METHODS AND RESULTS

The ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) trial included 7141 patients with acute heart failure from 30 countries. Country income data in gross national income per capita in current US dollars from the year 2007 (ie, the year trial enrollment began) were abstracted from the World Bank. Patients were grouped by enrolling country income level (ie, high [>$11 455], upper middle [$3706-$11 455], lower middle [$936-$3705], and low [<$936]). Income data were available for 29 (97%) countries (N=7064). There were 3996 (57%), 1518 (21%), and 1550 (22%) patients from high-income, upper-middle-income, and lower-middle-income countries, respectively. There were no patients from low-income countries. Patients from lower-middle-income countries tended to be younger with fewer comorbidities and lower utilization of guideline-directed therapies. Rates of adverse events (13.8%) and protocol noncompletion (4.9%) during 180-day follow-up were highest among high-income countries (all P <0.01). After adjustment for race, geographic region, and clinical characteristics, compared with lower-middle-income countries, enrollment from higher income countries was associated with increased 30-day mortality or rehospitalization (high income: odds ratio, 1.70; 95% CI, 1.02-2.85; upper-middle-income: odds ratio, 2.16; 95% CI, 1.23-3.81), driven by higher rates of rehospitalization. Mortality was similar at 30 and 180 days. The association between higher country income and the 30-day composite end point was similar across geographic regions, with exception of Latin America ( P for interaction, 0.03).

CONCLUSIONS

In this global acute heart failure trial, patients from higher income countries had lower rates of protocol completion, higher rates of adverse events, and similar mortality rates. After adjustment for race, geographic region, and clinical factors, enrollment from a higher income country was associated with worse clinical outcomes, driven by higher rates of rehospitalization. Variation in enrolling country income level may influence study end points and trial performance independent of geographic region.

CLINICAL TRIAL REGISTRATION

URL: https://www.clinicaltrials.gov . Unique identifier: NCT00475852.

摘要

背景

临床试验的全球化促使高收入和低收入国家都被纳入其中,但入选国家的收入水平对心力衰竭试验结果的影响尚不清楚。本研究旨在评估入选国家收入水平、急性心力衰竭患者特征、方案完成情况和试验终点之间的关联。

方法与结果

急性失代偿性心力衰竭患者奈西立肽临床有效性急性研究(ASCEND-HF)试验纳入了来自30个国家的7141例急性心力衰竭患者。2007年(即试验开始招募的年份)以当前美元计算的人均国民总收入的国家收入数据摘自世界银行。患者按入选国家的收入水平分组(即高收入[>11455美元]、中高收入[3706-11455美元]、中低收入[936-3705美元]和低收入[<936美元])。29个(97%)国家有收入数据(N=7064)。分别有3996例(57%)、1518例(21%)和1550例(22%)患者来自高收入、中高收入和中低收入国家。没有来自低收入国家的患者。中低收入国家的患者往往更年轻,合并症更少,且指南指导治疗的使用率更低。在180天随访期间,高收入国家的不良事件发生率(13.8%)和方案未完成率(4.9%)最高(所有P<0.01)。在对种族、地理区域和临床特征进行调整后,与中低收入国家相比,高收入国家的入选与30天死亡率或再住院率增加相关(高收入:比值比,1.70;95%CI,1.02-2.85;中高收入:比值比,2.16;95%CI,1.23-3.81),这是由更高的再住院率驱动的。30天和180天的死亡率相似。除拉丁美洲外,不同地理区域国家收入较高与30天综合终点之间的关联相似(交互作用P=0.03)。

结论

在这项全球急性心力衰竭试验中,高收入国家的患者方案完成率较低,不良事件发生率较高,死亡率相似。在对种族、地理区域和临床因素进行调整后,高收入国家的入选与更差的临床结局相关,这是由更高的再住院率驱动的。入选国家收入水平的差异可能独立于地理区域影响研究终点和试验结果。

临床试验注册

网址:https://www.clinicaltrials.gov 。唯一标识符:NCT-

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb62/6208149/dead967452c7/nihms-1506717-f0001.jpg

相似文献

引用本文的文献

1
Neurohumoral Activation in Heart Failure.心力衰竭中的神经体液激活。
Int J Mol Sci. 2023 Oct 23;24(20):15472. doi: 10.3390/ijms242015472.

本文引用的文献

3
Globalization of heart failure trials: no turning back on this paradigm.心力衰竭试验的全球化:这一范式不可逆转。
Eur Heart J. 2016 Nov 1;37(41):3175-3177. doi: 10.1093/eurheartj/ehw326. Epub 2016 Jul 28.
10
The war against heart failure: the Lancet lecture.与心力衰竭作斗争:柳叶刀演讲。
Lancet. 2015 Feb 28;385(9970):812-24. doi: 10.1016/S0140-6736(14)61889-4. Epub 2014 Nov 16.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验